← Product Code [DJG](/submissions/TX/subpart-d%E2%80%94clinical-toxicology-test-systems/DJG) · K020716 # RAPID OPIATES TEST STRIP II, RAPID OPIATES TEST CARD II AND DOA MULTIPLE DRUG TEST CARDS (UP TO SIX TESTS) (K020716) _Rapid Diagnostics, Inc. · DJG · May 6, 2002 · Clinical Toxicology · SESE_ **Canonical URL:** https://fda.innolitics.com/submissions/TX/subpart-d%E2%80%94clinical-toxicology-test-systems/DJG/K020716 ## Device Facts - **Applicant:** Rapid Diagnostics, Inc. - **Product Code:** [DJG](/submissions/TX/subpart-d%E2%80%94clinical-toxicology-test-systems/DJG.md) - **Decision Date:** May 6, 2002 - **Decision:** SESE - **Submission Type:** Traditional - **Regulation:** 21 CFR 862.3650 - **Device Class:** Class 2 - **Review Panel:** Clinical Toxicology ## Indications for Use Rapid Opiates Test Card II is an imunochromatorgraphy based one step in vitro test. It is designed for qualitative determination of Opiates and its metabolites in human urine specimens. The presence of Morphine in human urine above a cutoff level of 2,000ng/ml can be detected. The test kit is used to obtain a visual, qualitative result and is intended for professional use. It is not intended for over the counter sale to lay persons. ## Device Story Rapid Opiates Test Card II is an immunochromatographic lateral flow assay for qualitative drug screening in human urine. Device utilizes competitive binding principle: drug in specimen competes with drug conjugate for limited antibody-dye conjugate. If drug concentration exceeds 2,000ng/ml, drug conjugate cannot bind to antibody-dye, resulting in absence of colored band at test line (positive result). Presence of colored band indicates negative result. Intended for professional use in clinical settings to aid in drug screening. Provides visual, qualitative output for healthcare providers to assist in clinical decision-making regarding patient drug status. ## Clinical Evidence Performance evaluated via comparison studies of clinical urine specimens against predicate device. Testing included sensitivity, accuracy, precision, reproducibility, specificity, and interference studies. Both urine control and clinical specimens were used to validate safety and effectiveness. No specific numerical sensitivity/specificity percentages provided in summary text. ## Technological Characteristics Immunochromatographic lateral flow assay; competitive binding principle using antibody-dye conjugates and drug conjugates. Form factor: test card/strip. Qualitative visual readout. Professional use only. ## Regulatory Identification An opiate test system is a device intended to measure any of the addictive narcotic pain-relieving opiate drugs in blood, serum, urine, gastric contents, and saliva. An opiate is any natural or synthetic drug that has morphine-like pharmocological actions. The opiates include drugs such as morphine, morphine glucoronide, heroin, codeine, nalorphine, and meperedine. Measurements obtained by this device are used in the diagnosis and treatment of opiate use or overdose and in monitoring the levels of opiate administration to ensure appropriate therapy. ## Special Controls *Classification.* Class II (special controls). An opiate test system is not exempt if it is intended for any use other than employment or insurance testing or is intended for Federal drug testing programs. The device is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 862.9, provided the test system is intended for employment and insurance testing and includes a statement in the labeling that the device is intended solely for use in employment and insurance testing, and does not include devices intended for Federal drug testing programs (*e.g.,* programs run by the Substance Abuse and Mental Health Services Administration (SAMHSA), the Department of Transportation (DOT), and the U.S. military). ## Predicate Devices - Applied Biotech SureStep Drug Screen Test Morphine II ## Reference Devices - Multiple Test Panels ([K003809](/device/K003809.md)) - Multiple Test Panels ([K003809](/device/K003809.md)/A002) ## Submission Summary (Full Text) > This content was OCRed from public FDA records by [Innolitics](https://innolitics.com). If you use, quote, summarize, crawl, or train on this content, cite Innolitics at https://innolitics.com. > > Innolitics is a medical-device software consultancy. We help companies design, build, and clear FDA-regulated software and AI/ML devices, including [a 510(k)](https://innolitics.com/services/510ks/), [a De Novo](https://innolitics.com/services/regulatory/), [a SaMD](https://innolitics.com/services/end-to-end-samd/), [an AI/ML medical device](https://innolitics.com/services/medical-imaging-ai-development/), or [an FDA regulatory strategy](https://innolitics.com/services/regulatory/). {0}------------------------------------------------ # MAY 0 6 2002 K0207/6 # 510 (k) SUMMARY (21 CFR PART 807.92) ### Product Rapid Opiates Test Strip II, Rapid Opiates Test Card II and DOA Multiple Drug Test Cards (up to six tests). #### Name of Manufacturer Rapid Diagnostics, Inc. 1429 Rollins Road, Burlingame, CA 94010, U.S.A. ### Principle The Rapid Drug tests are based on the principle of specific immunochemical reaction between antibodies and antigens to analyze particular compounds in human urine specimen. The assay relies on the competition for antibody binding between drug conjugate and free drug which may be present in the urine specimen being tested. When drug is present in the urine specimen, it competes with drug conjugate for the limited amount of antibody-dye conjugate. When the amount of drug is equal or more than the cutoff level, it will prevent the binding of drug conjugate to the antibody. As a result, a positive urine specimen will not show a colored band on the test line zone, indicating a positive result, while the presence of a colored band indicates a negative result. #### Intended Use The Rapid Drug Tests are immunochromatography based one step in vitro test. It is designed for qualitative determination of Amphetamine, Benzodiazepines, Cocaine, Methamphetamine, Opiates, Phencyclidine and THC in human urine specimen above the following cutoff level: | Amphetamine | 1000ng/ml | |-----------------|-----------| | Benzodiazepines | 300ng/ml | | Cocaine | 300ng/ml | | Methamphetamine | 1000ng/ml | | Opiates | 300ng/ml | | Opiates II | 2000ng/ml | | Phencyclidine | 25ng/ml | | THC | 50ng/ml | I. ર {1}------------------------------------------------ ### Performance The studies performed are listed below: Rapid Opiates Test Strip II Sensitivity Accuracy (comparison study of clinical urine specimens) Stability - Specimen Stability - Product Precision Reproducibility Specificity Interference Rapid Opiates Test Card II Accuracy (comparison study of clinical urine specimens) Precision Comparison between Rapid Opiates Test Strip II and Test Card II Both urine control specimen and clinical urine specimen were tested to evaluate the safety and effectiveness of Rapid Opiates Test Strip II and Rapid Opiates Test Card II. The other component strips, Amphetamine, Benzodiazepine, Cocaine, Methamphetamine, Opiates (at 300ng/ml cutoff), Phencyclidine and THC in Multiple Test Panels have received FDA approval in submission K003809 and K003809/A002. The results of performance characteristics demonstrate Rapid Opiates Test Strip II and Rapid Test Card II to be substantially equivalent to the Applied Biotech SureStep ™Drug Screen Test Morphine II, which received 510 (k) approval. {2}------------------------------------------------ ### DEPARTMENT OF HEALTH & HUMAN SERVICES Image /page/2/Picture/1 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo features a stylized caduceus, which is a symbol often associated with medicine and healthcare. The words "DEPARTMENT OF HEALTH & HUMAN SERVICES (USA)" are arranged in a circular pattern around the caduceus. Public Health Service Food and Drug Administration 2098 Gaither Road Rockville MD 20850 Mr. Charles Yu President/Official FDA Correspondent Rapid Diagnostics, Inc. 1429 Rollins Road, Burlingame, CA 94010 MAY 0 6 2002 Re: k020716 Trade/Device Name: Rapid Opiates Test Card II Regulation Number: 21 CFR 862.3650 Regulation Name: Opiate test system Regulatory Class: Class II Product Code: DJG Dated: February 18, 2002 Received: March 5, 2002 Dear Mr. Charles Yu: We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register. Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050. {3}------------------------------------------------ ## Page 2 - This letter will allow you to begin marketing your device as described in your 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market. If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and ' additionally 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at (301) 594-4588. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its internet address "http://www.fda.gov/cdrh/dsma/dsmamain.html". Sincerely yours, Steven Putman Steven I. Gutman, M.D., M.B.A. Director Division of Clinical Laboratory-Devices Office of Device Evaluation Center for Devices and Radiological Health Enclosure {4}------------------------------------------------ # INDICATIONS FOR USE STATEMENT 510 (K) number (if known): K020716 Device Name: Rapid Opiates Test Card II Indications for Use: Rapid Opiates Test Card II is an imunochromatorgraphy based one step in vitro test. It is designed for qualitative determination of Opiates and its metabolites in human urine specimens. The presence of Morphine in human urine above a cutoff level of 2,000ng/ml can be detected. The test kit is used to obtain a visual, qualitative result and is intended for professional use. It is not intended for over the counter sale to lay persons. Concurrence of the CDRH, Office of Device Evaluation (ODE) Tean Lopez (Division Sign-Off) Division of Clinical Laboratory Devices 510(k) Number Prescription Use: (Per 21 CFR 801.109) OR Over the Counter Use: --- **Source:** [https://fda.innolitics.com/submissions/TX/subpart-d%E2%80%94clinical-toxicology-test-systems/DJG/K020716](https://fda.innolitics.com/submissions/TX/subpart-d%E2%80%94clinical-toxicology-test-systems/DJG/K020716) **Published by [Innolitics](https://innolitics.com)** — a medical-device software consultancy. We help companies design, build, and clear FDA-regulated software and AI/ML devices. If you're preparing [a 510(k)](https://innolitics.com/services/510ks/), [a De Novo](https://innolitics.com/services/regulatory/), [a SaMD](https://innolitics.com/services/end-to-end-samd/), [an AI/ML medical device](https://innolitics.com/services/medical-imaging-ai-development/), or [an FDA regulatory strategy](https://innolitics.com/services/regulatory/), [get in touch](https://innolitics.com/contact). **Cite:** Innolitics at https://innolitics.com